📖 Your Q2 Earnings Guide: Discover the Stocks ProPicks AI Highlights to Jump Post-EarningsRead more

GSK share maintains Buy rating on recent developments

EditorNatashya Angelica
Published 06/20/2024, 11:31 AM
GSK
-
GSK
-

On Thursday, Berenberg reaffirmed its Buy rating on GlaxoSmithKline (NYSE:GSK:LN) (NYSE: GSK), maintaining a price target of £18.20 for the pharmaceutical giant's shares. The endorsement comes as the market reacts to recent developments, including a judge's ruling on the Zantac case and updates to GSK's oncology pipeline.

The firm's position follows a period of adjustment for GSK's stock, which had experienced movement in the wake of the legal decision in Delaware concerning Zantac, a medication previously sold by GSK. Moreover, the company has been updating investors on the progress of its oncology treatments.

The focus is now shifting to GSK's newly launched vaccine, Arexvy. Significant attention is being directed toward the upcoming presentation of new data to the US vaccines committee, scheduled for June 26, 2024. The outcome of this presentation will be instrumental in establishing the final immunisation schedule for the vaccine.

Analysts anticipate that GSK could benefit from a broader immunisation recommendation that includes younger, at-risk populations. Such an expansion would potentially increase the vaccine's market and bolster the company's revenue stream from this product.

Despite the potential for growth with Arexvy, GSK's stock continues to be weighed down by the ongoing Zantac litigation. Still, Berenberg suggests that the current share price already accounts for the associated risks of this legal issue, indicating that the market has integrated this factor into GSK's valuation.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.